181 related articles for article (PubMed ID: 32220889)
1. Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia.
Laurent AP; Siret A; Ignacimouttou C; Panchal K; Diop M; Jenni S; Tsai YC; Roos-Weil D; Aid Z; Prade N; Lagarde S; Plassard D; Pierron G; Daudigeos E; Lecluse Y; Droin N; Bornhauser BC; Cheung LC; Crispino JD; Gaudry M; Bernard OA; Macintyre E; Barin Bonnigal C; Kotecha RS; Geoerger B; Ballerini P; Bourquin JP; Delabesse E; Mercher T; Malinge S
Clin Cancer Res; 2020 Jul; 26(13):3307-3318. PubMed ID: 32220889
[TBL] [Abstract][Full Text] [Related]
2. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Dai X; Xia H; Zhou S; Tang Q; Bi F
Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
[TBL] [Abstract][Full Text] [Related]
6. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by
Chu SH; Song EJ; Chabon JR; Minehart J; Matovina CN; Makofske JL; Frank ES; Ross K; Koche RP; Feng Z; Xu H; Krivtsov A; Nussenzweig A; Armstrong SA
Blood Adv; 2018 Oct; 2(19):2478-2490. PubMed ID: 30266823
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
9. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
11. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
12. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
[TBL] [Abstract][Full Text] [Related]
13. Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers.
Mittal S; Sharma A; Balaji SA; Gowda MC; Dighe RR; Kumar RV; Rangarajan A
Mol Cancer Ther; 2014 Dec; 13(12):3198-3209. PubMed ID: 25253780
[TBL] [Abstract][Full Text] [Related]
14. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
Jones CL; Gearheart CM; Fosmire S; Delgado-Martin C; Evensen NA; Bride K; Waanders AJ; Pais F; Wang J; Bhatla T; Bitterman DS; de Rijk SR; Bourgeois W; Dandekar S; Park E; Burleson TM; Madhusoodhan PP; Teachey DT; Raetz EA; Hermiston ML; Müschen M; Loh ML; Hunger SP; Zhang J; Garabedian MJ; Porter CC; Carroll WL
Blood; 2015 Nov; 126(19):2202-12. PubMed ID: 26324703
[TBL] [Abstract][Full Text] [Related]
15. Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders.
Ogasawara T; Yasuyama M; Kawauchi K
Int J Hematol; 2003 May; 77(4):364-70. PubMed ID: 12774925
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
[TBL] [Abstract][Full Text] [Related]
17. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
[TBL] [Abstract][Full Text] [Related]
18. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
19. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.
Meel MH; Guillén Navarro M; de Gooijer MC; Metselaar DS; Waranecki P; Breur M; Lagerweij T; Wedekind LE; Koster J; van de Wetering MD; Schouten-van Meeteren N; Aronica E; van Tellingen O; Bugiani M; Phoenix TN; Kaspers GJL; Hulleman E
Neuro Oncol; 2020 Jan; 22(1):58-69. PubMed ID: 31504799
[TBL] [Abstract][Full Text] [Related]
20. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]